Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries

References

• Pollack CV Jr., Amin A, Ford WT, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508–519.
   PubMed Web of Science ®Google Scholar
• LaPensee K, Fan W, Wang Y. Economic burden of hospitalization with antibiotic treatment for Absssi in the United States: an analysis of the premier hospital database. Value Health. 2012;15(4):A240–A241.
   PubMed Web of Science ®Google Scholar
• DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53(Suppl 2):ii37–ii50.
   PubMedGoogle Scholar
• Health Protection Agency. English national point prevalence survey on healthcare associated infections and antimicrobial use, 2011. London: Health Protection Agency; 2012.
   Google Scholar
• Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112–e146.
   PubMed Web of Science ®Google Scholar
• Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–661.
   PubMed Web of Science ®Google Scholar
• Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY antimicrobial surveillance program (1998–2004). Diagn Microbiol Infect Dis. 2007;57(1):7–13.
   PubMed Web of Science ®Google Scholar
• Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018;4:18033.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. S. ECDC; Editor; 2018.
   Google Scholar
• Ventola CL. The antibiotic resistance crisis: part 2: management strategies and new agents. Pharm Ther. 2015;40(5):344–352.
   Google Scholar
• Bamberger DM. Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin. Ther Clin Risk Manag. 2007;3(4):675–684.
   PubMedGoogle Scholar
• Bhavnani SM, Prakhya A, Hammel JP, et al. Cost-effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infect Dis. 2009;49(5):691–698.
   PubMed Web of Science ®Google Scholar
• Choo EJ, Chambers HF. Treatment of methicillin-resistant Staphylococcus aureus bacteremia. Infect Chemother. 2016;48(4):267–273.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):e10–e52.
   PubMed Web of Science ®Google Scholar
• Bal AM, David MZ, Garau J, et al. Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen. J Glob Antimicrob Resist. 2017;10:295–303.
   PubMed Web of Science ®Google Scholar
• Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16(13):2073–2081.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves dalvance to treat skin infections; 2014 [cited Dec 2018]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm398724.htm
   Google Scholar
• European Medicines Agency. Xydalba authorisation details; 2015 [cited 2017]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human_med_001848.jsp&mid=WC0b01ac058001d12
   Google Scholar
• Eckmann C, Lawson W, Nathwani D, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014;44(1):56–64.
   PubMed Web of Science ®Google Scholar
• Desai M, Franklin BD, Holmes AH, et al. A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis. 2006;6:94.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Eurostat. Eurostat data 2014; 2017. [cited Dec 2018]. Available from: http://ec.europa.eu/eurostat/data/database
   Google Scholar
• Jensen IS, Lodise TP, Fan W, et al. Use of oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics: a US hospital budget impact analysis. Clin Drug Investig. 2016;36(2):157–168.
   PubMed Web of Science ®Google Scholar
• Farmaco, A.I.d. Tabelle farmaci di classe A e H al 15/09/2017; 2017. [cited Dec 2018]. Available from: http://www.aifa.gov.it/content/tabelle-farmaci-di-classe-e-h-al-15092017
   Google Scholar
• Ministerio de Sanidad. Servicios Sociales e Igualdad. Nomenclátor de Facturación de Diciembre −2017; 2017. [cited Dec 2018]. Available from: https://www.msssi.gob.es/profesionales/nomenclator.do
   Google Scholar
• Ministero della salute. Nomenclatore tariffario dell’assistenza specialistica ambulatoriale. Decreto del 18 ottobre; 2012.
   Google Scholar
• Vasco G. Tarifas para facturación de servicios sanitarios y docentes de osakidetza para el año 2016. Erakunde zentrala organización central, Editor; 2015 Dicembre.
   Google Scholar
• D’Attis A, Mastrandrea G, Conte A, et al. Cateteri venosi centrali: equilibrio tra efficacia ed economicità. ed. A. editore. 2013.
   Google Scholar
• Pikwer A, Akeson J, Lindgren S. Complications associated with peripheral or central routes for central venous cannulation. Anaesthesia. 2012;67(1):65–71.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford handbooks in health economic evaluation. Oxford: Oxford University Press; 2006. p. x, 237.
   Google Scholar
• Mennini F, Marcellusi A, Bini C, et al. Dalbavancina in pazienti affetti da ABSSSI Analisi di impatto economico e organizzativo. I supplementi di Politiche sanitarie. 2017;5–16.
   Google Scholar
• Fundación para la Formación e Investigación Sanitarias de la Región de Murcia. Precios públicos pruebas realizadas en el Servicio Murciano de Salud según BORM 28-febrero-2017; 2017 [cited 2018 Mar 1]. Available from: http://www.ffis.es/investigacion/precios_pruebas.php
   Google Scholar
• Ministerul Sanatii. Catalogul national al preturilor la medicamentele de uz uman eliberate cu prescriptie medicala, autorizate de punere pe piata; 2017. [cited Dec 2018]. Available from: http://preturi.ms.ro/interogare.php
   Google Scholar
• van Zanten AR, Engelfriet PM, van Dillen K, et al. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care. 2003;7(6):R184–R190.
   PubMed Web of Science ®Google Scholar
• Hoekstra H, Smeets B, Metsemakers W-J, et al. Economics of open tibial fractures: the pivotal role of length-of-stay and infection. Health Econ Rev. 2017;7(1):32.
   PubMedGoogle Scholar
• Blumberg TJ, Woelber E, Bellabarba C, et al. Predictors of increased cost and length of stay in the treatment of postoperative spine surgical site infection. Spine J. 2018 Feb;18(2):300-306.
   Google Scholar
• Andreassen AES, Jacobsen CM, de Blasio B, et al. The impact of methicillin-resistant S. aureus on length of stay, readmissions and costs: a register based case-control study of patients hospitalized in Norway. Antimicrob Resist Infect Control. 2017;6:74.
   PubMed Web of Science ®Google Scholar
• Amelung S, Meid AD, Nafe M, et al. Association of preventable adverse drug events with inpatients’ length of stay-A propensity-matched cohort study. Int J Clin Pract. 2017;71(10):e12990.
   PubMed Web of Science ®Google Scholar
• Periard D, Monney P, Waeber G, et al. Randomized controlled trial of peripherally inserted central catheters vs. peripheral catheters for middle duration in-hospital intravenous therapy. J Thromb Haemost. 2008;6(8):1281–1288.
   PubMed Web of Science ®Google Scholar
• Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77(11):1143–1154.
   PubMed Web of Science ®Google Scholar
• Guest JF, Esteban J, Manganelli AG, et al. Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: results of a network meta-analysis. PLoS One. 2017;12(11):e0187792.
   PubMed Web of Science ®Google Scholar
• Jones M, Ying J, Huttner B, et al. Relationships between the importation, transmission, and nosocomial infections of methicillin-resistant Staphylococcus aureus: an observational study of 112 veterans affairs medical centers. Clin Infect Dis. 2014;58(1):32–39.
   PubMed Web of Science ®Google Scholar
• Wolkewitz M, Casarin A. Multilevel competing risk models to evaluate the risk of nosocomial infection. Crit Care. 2014;18(2):R64.
   PubMed Web of Science ®Google Scholar
• Browne C, Muszbek N, Chapman R, et al. Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin. Int J Antimicrob Agents. 2016;47(5):357–361.
   PubMed Web of Science ®Google Scholar
• Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013;5:447–457.
   PubMedGoogle Scholar
• Ektare V, Khachatryan A, Xue M, et al. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting. J Med Econ. 2015;18(12):1092–1101.
   PubMed Web of Science ®Google Scholar